# South America Thyroid Disorder Market

> South America Thyroid Disorder Market Research Report By Type (Hypothyroidism, Hyperthyroidism), By Treatment (Medications, Radioactive Iodine Therapy, Surgery), By Route of Administration (Oral, Intravenous, others), By End User (Hospitals, Clinics, others) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.16%
- **2024:** $ 200.9 Million
- **2025:** $ 209.26 Million
- **2035:** $ 314.41 Million
- **Key Players:** AbbVie Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), GlaxoSmithKline plc (GB), Merck & Co., Inc. (US), Novartis AG (CH), Pfizer Inc. (US), Sanofi S.A. (FR), Takeda Pharmaceutical Company Limited (JP)

**Report ID:** MRFR/MED/55242-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-thyroid-disorder-market-57008

---

## Market Summary

## **South America Thyroid Disorder Market Overview**

As per MRFR analysis, the South America Thyroid Disorder Market Size was estimated at 241 (USD Million) in 2024. The South America Thyroid Disorder Market Industry is expected to grow from 353 (USD Million) in 2025 to 522 (USD Million) by 2035. The South America Thyroid Disorder Market CAGR (growth rate) is expected to be around 3.62% during the forecast period (2025 - 2035).

### **Key South America Thyroid Disorder Market Trends Highlighted**

The South America Thyroid Disorder Market is experiencing significant changes driven by a combination of factors. An increasing prevalence of thyroid disorders, such as hypothyroidism and hyperthyroidism, has emerged as a key market driver. Reports indicate a growing awareness and diagnosis of these conditions across the region, partially fueled by improved access to healthcare facilities and diagnostic tools.

As countries like Brazil, Argentina, and Chile advance their healthcare infrastructure, the need for effective thyroid disorder management grows. Furthermore, genetic predisposition and lifestyle factors are contributing to the rise of these disorders in South America. In terms of opportunities to be explored, the demand for innovative treatment solutions offers promising avenues for development.

The market is seeing a shift towards personalized medicine and biologics, which cater to individual patient needs. This trend is increasingly visible in urban areas where patients are more inclined to seek advanced therapeutics. Additionally, ongoing research into alternative therapies, including natural and holistic approaches, represents another space where companies can expand their offerings.

Trends in recent times also highlight a surge in telemedicine services in the region, driven by the COVID-19 pandemic. Patients are opting for virtual appointments for diagnosis and management of thyroid disorders, ensuring continuous care and support. This shift not only enhances patient access but also provides healthcare providers with valuable data insights.

Overall, the South America Thyroid Disorder Market showcases a dynamic environment driven by increased awareness, technological advances, and a growing emphasis on patient-centered care

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **South America Thyroid Disorder Market Drivers**

### **Increasing Prevalence of Thyroid Disorders**

The South America [Thyroid Disorder Market](../../../reports/thyroid-disorder-market-2747) Industry is significantly driven by the rising prevalence of thyroid disorders across the region. According to the Ministry of Health of Brazil, thyroid diseases, particularly hypothyroidism, affect approximately 10% of the population, translating to around 21 million individuals in Brazil alone. This high prevalence rate indicates a growing patient pool requiring medical attention and treatment options for thyroid disorders.

Moreover, the growing awareness of thyroid health and the effort to improve screening programs in South American countries, such as Argentina and Colombia, contribute to earlier diagnosis and treatment. Established organizations like the Brazilian Society of Endocrinology and Metabolism are actively promoting awareness campaigns, which has a notable impact on driving the demand for thyroid disorder therapies and diagnostics across South America.

### **Advancements in Diagnostic Technologies**

The South America Thyroid Disorder Market Industry is witnessing growth due to advancements in diagnostic technologies. Innovations such as highly sensitive thyroid function tests and the introduction of molecular diagnostics play a crucial role in enhancing diagnosis accuracy and speed. A report from the Argentine Ministry of Health indicated a 25% increase in the accuracy of thyroid testing due to the recent adoption of advanced technologies in laboratory settings.

Besides, groups like the World Health Organization have highlighted the need for sophisticated and streamlined laboratory services for thyroid disorder diagnosis, which improves treatment pathways. These advancements in technology not only make timely treatment intervention easier but also aid in expanding the market.

### **Increasing Health Expenditure in South America**

Another driving factor for the South America Thyroid Disorder Market Industry is the increasing health expenditure across various South American nations. Reports indicate that health expenditure has been rising at an average rate of 5-7% annually, with several countries such as Chile and Uruguay investing heavily in healthcare services, including endocrinology.

According to Chile's Ministry of Health, health spending is expected to reach approximately 10.2% of the country's GDP by 2025, emphasizing the commitment to improving healthcare infrastructure. This surge in health expenditure reflects the growing prioritization of health issues, including thyroid disorders, leading to enhanced funding for research, diagnostics, and treatment modalities by public and private sectors alike.

## **South America Thyroid Disorder Market Segment Insights**

### **Thyroid Disorder Market Type Insights**

The South America Thyroid Disorder Market is categorized into key types including Hypothyroidism and Hyperthyroidism, which play crucial roles in the region's healthcare landscape. Hypothyroidism, characterized by an underactive thyroid, significantly impacts the lives of many individuals, particularly women, making it one of the most prevalent thyroid-related disorders in South America.

This segment has been gaining attention due to the increasing awareness about thyroid health and its association with various health issues such as obesity and cardiovascular risk. As healthcare systems in South America continue to enhance screening measures and improve patient education, the prevalence of hypothyroidism is expected to grow, driving demand for various treatment options.

On the other hand, Hyperthyroidism is another significant type within the South America Thyroid Disorder Market, which occurs due to an overactive thyroid gland. This condition typically leads to symptoms such as weight loss, anxiety, and increased heart rate. The growing occurrence of hyperthyroidism, particularly in urban populations due to lifestyle changes and environmental factors, illustrates the need for widespread diagnosis and management solutions.

Both segments are interlinked, as effective management of thyroid disorders requires comprehensive approaches encompassing medication, lifestyle changes, and regular monitoring. The growing emphasis on preventive healthcare and advances in treatment alternatives present opportunities for healthcare providers and pharmaceutical companies in South America to address the critical needs of patients suffering from these thyroid conditions.

Overall, the focus on awareness, early diagnosis, and innovative treatment options continues to shape the South America Thyroid Disorder Market, showcasing the importance of both Hypothyroidism and Hyperthyroidism in the region's health dynamics.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Thyroid Disorder Market Treatment Insights**

The Treatment segment of the South America Thyroid Disorder Market encompasses various methodologies including Medications, Radioactive Iodine Therapy, and Surgery, playing a pivotal role in managing thyroid disorders prevalent in the region. With a growing awareness of thyroid health, patient access to innovative treatment options is increasing, leading to a rise in utilization.

Medications are crucial as they directly address hormone imbalances, becoming a primary choice for many patients managing conditions such as hypothyroidism and hyperthyroidism. Radioactive Iodine Therapy is significant in treating hyperthyroidism and specific thyroid cancers, with its effectiveness driving demand in clinical practices.

Moreover, Surgery remains a vital option, especially in cases of large goiters or malignancies, as it provides definitive solutions for patients needing long-term management. The South America Thyroid Disorder Market is experiencing a steady evolution, influenced by advancements in medical technology and growing healthcare infrastructure.

Additionally, as the prevalence of thyroid disorders rises, there are opportunities for innovative treatments and personalized medicine approaches, reflecting changing patient needs. Overall, the Treatment segment is essential for addressing the needs of patients and improving thyroid health outcomes across South America.

### **Thyroid Disorder Market Route of Administration Insights**

The Route of Administration segment in the South America Thyroid Disorder Market plays a crucial role in determining treatment effectiveness and patient compliance. Oral administration is often favored for thyroid hormone replacement therapies due to its convenience and ease of use, thus establishing a strong foothold in the market.

Intravenous administration, meanwhile, is essential for acute management scenarios, particularly in cases where immediate therapeutic action is required. Other routes, such as subcutaneous and intramuscular options, complement these methods, providing alternative avenues for therapy in specific patient populations.

The market is characterized by an increasing demand for effective and patient-friendly delivery options, driven by rising awareness and diagnosis of thyroid disorders in South America. Additionally, ongoing advancements in pharmaceutical formulations are aimed at improving bioavailability and patient adherence, thereby enhancing overall treatment outcomes.

As the South America Thyroid Disorder Market continues to grow, the focus on refining routes of administration remains pivotal, supporting broader market dynamics and healthcare practices in the region.

### **Thyroid Disorder Market End User Insights**

The ser segment of the South America Thyroid Disorder Market plays a crucial role in delivering healthcare solutions to patients suffering from thyroid-related problems. With a growing emphasis on early diagnosis and effective treatment, hospitals and healthcare clinics are increasingly equipped to handle thyroid disorders, offering specialized services and advanced technologies.

Hospitals often dominate this segment due to their comprehensive facilities and access to multidisciplinary teams. Clinics, on the other hand, provide more personalized care and convenience for patients seeking thyroid evaluation and treatment, thereby gaining significant traction.

Moreover, other healthcare providers, such as outpatient facilities and telehealth services, are emerging to cater to the expanding patient base in South America. This diversification allows patients various options, making treatment more accessible. The rising awareness regarding thyroid disorders, coupled with increasing healthcare expenditure, drives the demand for these services.

In addition, the ongoing developments in healthcare infrastructure in countries like Brazil and Argentina are expected to bolster the growth of this segment, making it an integral part of the overall South America Thyroid Disorder Market statistics.

### **Thyroid Disorder Market Regional Insights**

The South America Thyroid Disorder Market is characterized by a diverse set of conditions across its various regions, significantly impacting healthcare policies and practices. Brazil holds a dominant position, reflecting a high prevalence of thyroid disorders influenced by urbanization and lifestyle changes.

Mexico ranks next, where healthcare access and awareness are steadily improving, leading to an increasing diagnosis of thyroid issues. Argentina showcases a growing recognition of thyroid health, propelled by governmental health initiatives aiming to educate the public and improve early detection.

Meanwhile, the Rest of South America segment benefits from regional collaborations and advancements in medical technology that enhance diagnosis and treatment. Overall, these regions present a substantial opportunity for growth, driven by rising healthcare expenditure, increasing incidence rates, and the development of new therapeutic options for managing thyroid disorders.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **South America Thyroid Disorder Market Key Players and Competitive Insights**

The South America Thyroid Disorder Market is witnessing notable competitive dynamics as the region grapples with a rising incidence of thyroid disorders, including hypothyroidism and hyperthyroidism, which has propelled demand for effective diagnostics and therapeutics.

The competitive landscape consists of various global and local companies seeking to enhance their market share through innovative products, strategic collaborations, and expanding distribution networks. As the healthcare infrastructure in South America evolves, companies are increasingly focusing on tailored treatment options and improving access to their products across diverse geographical areas.

With a growing emphasis on patient health outcomes, the market's competitive insights reflect the importance of understanding regional needs, regulatory environments, and consumer preferences for thyroid-related healthcare.

GlaxoSmithKline has carved a significant presence in the South America Thyroid Disorder Market by leveraging its extensive portfolio of therapeutic options targeted at managing thyroid conditions. The company’s strengths include robust research and development capabilities, enabling the introduction of innovative treatments that meet the specific needs of the South American population.

By focusing on partnerships with local healthcare institutions and facilitating training programs for healthcare professionals, GlaxoSmithKline enhances the quality of thyroid care in the region. The company's strategic commitment to addressing local health challenges, coupled with its established distribution channels, positions it as a key player in meeting the needs of patients with thyroid disorders across South America.

BristolMyers Squibb has also established its foothold in the South America Thyroid Disorder Market with its diverse range of products aimed at treating thyroid dysfunction. The company’s key offerings include both traditional pharmaceutical solutions and novel therapeutic approaches addressing thyroid disorders.

Its strengths lie in its innovative research and significant investment in local collaborations, which allow for the expedited development and distribution of its products. BristolMyers Squibb is known for its strategic mergers and acquisitions, enhancing its capabilities and service offerings in the region.

This approach not only strengthens its product pipeline but also improves its market presence in South America, ensuring that patients have better access to the necessary therapies for thyroid disorders. The company's commitment to improving patient outcomes further solidifies its position within the competitive landscape of the region's thyroid disorder market.

### **Key Companies in the South America Thyroid Disorder Market Include**

- GlaxoSmithKline
- BristolMyers Squibb
- Eli Lilly and Company
- Takeda Pharmaceutical Company
- [Abbott Laboratories](https://www.abbott.in/thyroid-disorder.html)
- Amgen Inc.
- Teva Pharmaceutical Industries
- Sanofi
- Merck KGaA
- Pfizer Inc.
- Boehringer Ingelheim
- Roche Holding AG
- AstraZeneca
- Johnson & Johnson
- Novartis AG

### **South America Thyroid Disorder Market Industry Developments**

Recent developments in the South America Thyroid Disorder Market have highlighted a growing focus on enhancing treatment options and expanding the availability of medication. Companies such as GlaxoSmithKline, Bristol-Myers Squibb, and Eli Lilly and Company are actively engaged in research to develop innovative therapies tailored to the specific needs of South American patients.

Notably, in September 2023, Takeda Pharmaceutical Company announced a partnership to enhance the distribution of thyroid-related medications across Brazil, addressing the increasing demand for hyperthyroid and hypothyroid treatments. The market has seen substantial growth, with analysts predicting a rise in valuation attributed to improved healthcare infrastructure and rising healthcare awareness.

Additionally, in August 2023, Roche Holding AG made significant strides in improving diagnostic interventions for thyroid disorders, marking a critical step toward personalized medicine in this region. Over the last couple of years, Amgen Inc. and Sanofi also made efforts to establish local partnerships to streamline clinical trials and expedite approvals for new therapies.

These initiatives reflect a continuous effort to tackle thyroid disorders effectively and provide better healthcare solutions in South America.

## **South America Thyroid Disorder Market Segmentation Insights**

### **Thyroid Disorder Market Type Outlook**

- Hypothyroidism
- Hyperthyroidism

### **Thyroid Disorder Market Treatment Outlook**

- Medications
- Radioactive Iodine Therapy
- Surgery

### **Thyroid Disorder Market Route of Administration Outlook**

- Oral
- Intravenous
- Others

### **Thyroid Disorder Market End User Outlook**

- Hospitals
- Clinics
- Others

### **Thyroid Disorder Market Regional Outlook**

- Brazil
- Mexico
- Argentina
- Rest of South America

## Market Drivers

### Increased Focus on Preventive Healthcare

The shift towards preventive healthcare in South America is emerging as a significant driver for the thyroid disorder market. As healthcare systems evolve, there is a growing emphasis on early detection and prevention of chronic diseases, including thyroid disorders. This focus is leading to more comprehensive screening programs and health check-ups that include thyroid function tests. The potential for early intervention not only improves patient outcomes but also reduces long-term healthcare costs. Consequently, this trend is likely to enhance the market landscape, as more individuals are encouraged to participate in preventive measures, thereby increasing the demand for diagnostic and treatment services related to thyroid disorders.

### Rising Demand for Nutritional Supplements

The increasing awareness of the role of nutrition in managing thyroid disorders is driving the thyroid disorder market in South America. Many patients are turning to nutritional supplements, such as iodine, selenium, and vitamin D, to support thyroid function and overall health. This trend is particularly relevant given that deficiencies in these nutrients can exacerbate thyroid conditions. The market for dietary supplements is projected to grow, with estimates suggesting a compound annual growth rate (CAGR) of around 7% over the next few years. As more individuals seek holistic approaches to managing their thyroid health, the demand for these supplements is likely to rise, further contributing to the market's expansion.

### Increasing Prevalence of Thyroid Disorders

The rising incidence of thyroid disorders in South America is a crucial driver for the thyroid disorder market. Recent studies indicate that approximately 10% of the population may be affected by some form of thyroid dysfunction, with conditions such as hypothyroidism and hyperthyroidism becoming increasingly common. This trend is particularly pronounced among women, who are disproportionately affected, with estimates suggesting that they are five to eight times more likely to develop these disorders than men. The growing prevalence necessitates enhanced healthcare services and treatment options, thereby propelling the thyroid disorder market forward. Furthermore, as awareness of these conditions increases, more individuals seek diagnosis and treatment, further expanding the market's potential.

### Government Initiatives and Healthcare Policies

Government initiatives aimed at improving healthcare access and quality in South America significantly influence the thyroid disorder market. Various countries in the region have implemented policies to enhance screening programs for thyroid disorders, particularly in rural and underserved areas. For instance, initiatives to provide subsidized healthcare services and medications have been introduced, which may lead to increased diagnosis and treatment rates. Additionally, public health campaigns focusing on the importance of thyroid health are likely to raise awareness and encourage individuals to seek medical advice. These efforts could potentially increase the market size, as more patients are diagnosed and treated for thyroid-related conditions.

### Technological Advancements in Treatment Options

The [thyroid disorder market](../../../reports/thyroid-disorder-market-2747) is experiencing a transformation due to technological advancements in treatment options. Innovations in pharmaceuticals, such as the development of new synthetic thyroid hormones and targeted therapies, are enhancing treatment efficacy and patient outcomes. Moreover, minimally invasive surgical techniques for thyroidectomy are becoming more prevalent, reducing recovery times and improving patient satisfaction. The introduction of personalized medicine, which tailors treatment based on individual genetic profiles, is also gaining traction. These advancements not only improve the quality of care but also stimulate market growth as healthcare providers adopt these new technologies to better serve their patients.

## Future Outlook

The [Thyroid Disorder Market](https://www.marketresearchfuture.com/reports/thyroid-disorder-market-2747) is projected to grow at a 4.16% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

**New opportunities:**

- Development of telehealth platforms for remote patient monitoring.
- Investment in AI-driven diagnostic tools for early detection.
- Expansion of personalized medicine approaches tailored to individual patient profiles.

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs.

## Segment Insights

### By Type: Hypothyroidism (Largest) vs. Hyperthyroidism (Fastest-Growing)

In the South America thyroid disorder market, hypothyroidism holds a significant share, dominating the segment due to the higher prevalence of the condition among the population. This is attributed to various factors, including genetic predisposition, lifestyle changes, and dietary deficiencies that contribute to an increased incidence of hypothyroidism. Conversely, hyperthyroidism, while smaller in market share, is witnessing substantial attention and growth as healthcare awareness rises and early diagnosis improves. The growth trends for the thyroid disorder types are being driven by a combination of factors, including advancing medical technologies, improved diagnostic methods, and growing public awareness regarding thyroid health. The healthcare sector is focusing on both conditions, with targeted therapies and patient education initiatives encouraging patients to seek treatment sooner. These factors collectively contribute to a dynamic market environment, particularly for hyperthyroidism, which is on the cusp of significant growth as more individuals are diagnosed and treated.

Hypothyroidism (Dominant) vs. Hyperthyroidism (Emerging)

Hypothyroidism is recognized as the dominant segment within the South America thyroid disorder market, characterized by a substantial patient population and established treatment protocols. It predominantly affects women and is often linked to autoimmune conditions, making the need for routine screenings and long-term management essential. On the other hand, hyperthyroidism is emerging rapidly as a significant segment, driven by an increase in cases linked to lifestyle and health awareness trends. The differentiation in treatment approaches, ranging from medication to thyroidectomy, illustrates the unique challenges and opportunities within both segments. As healthcare providers enhance their focus on thyroid disorders, both hypothyroidism and hyperthyroidism are poised for distinct trajectories within the healthcare landscape.

### By Treatment: Medications (Largest) vs. Radioactive iodine therapy (Fastest-Growing)

The treatment segment is primarily dominated by medications, which hold the largest share in addressing thyroid disorders. This is due to the variety of available pharmaceutical options that cater to diverse patient needs, including synthetic hormones and antithyroid drugs. Surgery, while effective, is not as widely utilized due to its invasive nature compared to the oral convenience of medications. Radioactive iodine therapy, though historically significant, remains a smaller segment but is gaining traction as a non-surgical option to manage hyperthyroidism, contributing to its growth in recent years. Growth trends in the treatment segment are notably driven by the increasing prevalence of thyroid disorders, alongside rising awareness and diagnosis rates in South America. The preference for less invasive treatments favors medications and radioactive iodine therapy, as patients opt for convenience and reduced recovery times. Furthermore, advancements in pharmaceutical research and therapeutic techniques are likely to bolster the efficacy and safety of treatments, attracting more patients towards these solutions.

Medications (Dominant) vs. Surgery (Emerging)

Medications serve as the dominant force in the treatment segment for thyroid disorders, providing a range of options that allow for personalized patient care. They include synthetic thyroid hormones and antithyroid medications, which facilitate effective management of hypothyroidism and hyperthyroidism. Surgery, on the other hand, is identified as an emerging treatment option primarily used for severe cases where medications are less effective. While it poses higher risks and requires longer recovery, surgical interventions offer a definitive resolution for certain thyroid issues. The evolving landscape of these treatments demonstrates the importance of balancing patient preferences, efficacy, and safety in the management of thyroid disorders.

### By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing)

In the South America thyroid disorder market, the route of administration is primarily dominated by the oral segment, which holds the largest market share. This is largely attributed to the convenience and ease of administration for patients, leading to higher adoption rates. Conversely, the intravenous segment, although smaller, is experiencing rapid growth as it becomes increasingly adopted in clinical settings for cases requiring immediate therapeutic effects. Growth trends within this sector point towards an increasing preference for the oral route due to its non-invasive nature and the growing number of oral formulations being developed. The intravenous segment's growth is driven by advancements in technology and the need for rapid intervention in severe cases. Providers are continuously looking for effective solutions, further bolstering the market dynamics.

Oral (Dominant) vs. Intravenous (Emerging)

The oral route of administration is considered dominant in treating thyroid disorders due to its established effectiveness, patient compliance, and cost-effectiveness. Oral medications often come in user-friendly formats such as tablets and capsules, making them the preferred choice among healthcare providers and patients. On the other hand, the intravenous route is viewed as emerging, particularly in urgent care scenarios where rapid hormonal intervention is required. This route provides a more immediate response, which is crucial for managing acute thyroid conditions. The growing uptake of intravenous therapies reflects the evolving landscape of treatment options and the increasing focus on patient outcomes.

### By End-User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

The South America thyroid disorder market shows a diverse competitive landscape among end-users, with hospitals holding the largest market share. Hospitals account for a significant portion of the market due to their comprehensive treatment capabilities and advanced diagnostic tools. In contrast, clinics are rapidly gaining traction as healthcare providers adapt to outpatient treatment models, making them an increasingly important sector in thyroid disorder management. Overall, this distribution highlights the robustness of hospitals while showcasing the evolving dynamics of clinics.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals are characterized by their extensive range of services and infrastructure dedicated to managing thyroid disorders, making them the dominant players in this segment. Their ability to offer specialized care and a multidisciplinary approach positions them favorably in the market. On the other hand, clinics, while emerging in the segment, focus on outpatient care and often provide more accessible treatment options. This accessibility drives their growth as patients seek convenient solutions. Clinics can enhance patient engagement and tailored therapies, indicating a shifting trend in the healthcare landscape that favors both types of end-users.

## Regional Market Share Analysis

The South America Thyroid Disorder Market is characterized by a diverse set of conditions across its various regions, significantly impacting healthcare policies and practices. Brazil holds a dominant position, reflecting a high prevalence of thyroid disorders influenced by urbanization and lifestyle changes.

Mexico ranks next, where healthcare access and awareness are steadily improving, leading to an increasing diagnosis of thyroid issues. Argentina showcases a growing recognition of thyroid health, propelled by governmental health initiatives aiming to educate the public and improve early detection.

Meanwhile, the Rest of South America segment benefits from regional collaborations and advancements in medical technology that enhance diagnosis and treatment. Overall, these regions present a substantial opportunity for growth, driven by rising healthcare expenditure, increasing incidence rates, and the development of new therapeutic options for managing thyroid disorders.

## Competitive Benchmarking

The thyroid disorder market in South America is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as AbbVie Inc (US), Merck & Co., Inc. (US), and Novartis AG (CH) are actively pursuing strategies that enhance their market presence and operational efficiency. AbbVie Inc (US) focuses on developing novel therapies, which positions it favorably in a market that demands advanced treatment options. Meanwhile, Merck & Co., Inc. (US) emphasizes digital transformation and patient engagement, which are critical in enhancing treatment adherence and outcomes. Novartis AG (CH) is leveraging its extensive research capabilities to innovate in drug development, thereby contributing to a competitive environment that prioritizes cutting-edge solutions.
The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Pfizer Inc (US) and Sanofi S.A. (FR) suggests a trend towards consolidation, as these firms seek to strengthen their foothold through strategic collaborations and acquisitions.
In October 2025, Merck & Co., Inc. (US) announced a partnership with a local biotechnology firm to co-develop a new thyroid medication tailored for the South American market. This collaboration is significant as it not only enhances Merck's product portfolio but also allows for localized insights into patient needs, potentially leading to improved treatment outcomes. Such partnerships are indicative of a broader trend where multinational companies seek to integrate local expertise into their operational strategies.
In September 2025, Novartis AG (CH) launched a new digital health platform aimed at improving patient management for thyroid disorders. This initiative is crucial as it reflects the growing importance of technology in healthcare, particularly in managing chronic conditions. By utilizing digital tools, Novartis is likely to enhance patient engagement and adherence to treatment protocols, which could lead to better health outcomes and increased market share.
In August 2025, AbbVie Inc (US) expanded its research and development facilities in Brazil, focusing on innovative therapies for thyroid disorders. This expansion underscores AbbVie's commitment to the region and its strategy to tap into local talent and resources. By investing in R&D, AbbVie positions itself to lead in the development of next-generation therapies, which may provide a competitive edge in a rapidly evolving market.
As of November 2025, current trends in the thyroid disorder market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based strategies to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies approach market entry and product development, ultimately benefiting patients through improved treatment options.

## Recent News & Developments

Recent developments in the South America Thyroid Disorder Market have highlighted a growing focus on enhancing treatment options and expanding the availability of medication. Companies such as GlaxoSmithKline, Bristol-Myers Squibb, and Eli Lilly and Company are actively engaged in research to develop innovative therapies tailored to the specific needs of South American patients.

Notably, in September 2023, Takeda Pharmaceutical Company announced a partnership to enhance the distribution of thyroid-related medications across Brazil, addressing the increasing demand for hyperthyroid and hypothyroid treatments. The market has seen substantial growth, with analysts predicting a rise in valuation attributed to improved healthcare infrastructure and rising healthcare awareness.

Additionally, in August 2023, Roche Holding AG made significant strides in improving diagnostic interventions for thyroid disorders, marking a critical step toward personalized medicine in this region. Over the last couple of years, Amgen Inc. and Sanofi also made efforts to establish local partnerships to streamline clinical trials and expedite approvals for new therapies.

These initiatives reflect a continuous effort to tackle thyroid disorders effectively and provide better healthcare solutions in South America.

## Report Scope

| MARKET SIZE 2024 | 200.9(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 209.26(USD Million) |
| MARKET SIZE 2035 | 314.41(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.16% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | AbbVie Inc (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), GlaxoSmithKline plc (GB), Merck & Co., Inc. (US), Novartis AG (CH), Pfizer Inc. (US), Sanofi S.A. (FR), Takeda Pharmaceutical Company Limited (JP) |
| Segments Covered | Type, Treatment, Route of Administration, End-User |
| Key Market Opportunities | Emerging telehealth solutions enhance access to thyroid disorder management in South America. |
| Key Market Dynamics | Rising prevalence of thyroid disorders in South America drives demand for innovative treatment options and healthcare services. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What was the market valuation for thyroid disorders in South America in 2024?**
A: The market valuation for thyroid disorders in South America was $200.9 Million in 2024.

**Q: What is the projected market valuation for thyroid disorders in South America by 2035?**
A: The projected market valuation for thyroid disorders in South America is $314.41 Million by 2035.

**Q: What is the expected CAGR for the South America thyroid disorder market during the forecast period 2025 - 2035?**
A: The expected CAGR for the South America thyroid disorder market during the forecast period 2025 - 2035 is 4.16%.

**Q: Which companies are key players in the South America thyroid disorder market?**
A: Key players in the South America thyroid disorder market include AbbVie Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, and others.

**Q: What were the segment valuations for hypothyroidism and hyperthyroidism in 2024?**
A: In 2024, the segment valuation for hypothyroidism was $120.0 Million, while hyperthyroidism was $80.9 Million.

**Q: What treatment options are available for thyroid disorders in South America?**
A: Available treatment options include medications valued at $80.0 Million, surgery at $60.0 Million, and radioactive iodine therapy at $60.9 Million in 2024.

**Q: What routes of administration are utilized for thyroid disorder treatments?**
A: In 2024, the routes of administration included oral at $120.0 Million, intravenous at $30.0 Million, and other methods at $50.9 Million.

**Q: What are the end-user segments for thyroid disorder treatments in South America?**
A: End-user segments include hospitals valued at $120.27 Million, clinics at $40.18 Million, and others at $40.45 Million in 2024.

**Q: How does the market for thyroid disorders in South America compare to other regions?**
A: While specific comparisons to other regions are not provided, the growth trajectory suggests a robust market development in South America.

**Q: What factors may influence the growth of the thyroid disorder market in South America?**
A: Factors influencing growth may include advancements in treatment options, increasing awareness, and the rising prevalence of thyroid disorders.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-thyroid-disorder-market-57008*